| Jason A Maret, MD | |
|
1830 State Highway 9, Decorah, IA 52101-7301 | |
| (563) 382-3140 | |
| Not Available |
| Full Name | Jason A Maret |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 22 Years |
| Location | 1830 State Highway 9, Decorah, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215979554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 36515 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gundersen Regional Clinics, Llc | 8820450919 | 48 |
| Gundersen Clinic Ltd | 9638082779 | 359 |
News Archive
New research led by the University of Bristol, has shown the drug losartan, normally used to treat high blood pressure (hypertension), is not effective in slowing down the progression of Alzheimer's disease (AD) in people with mild-to-moderate disease after 12 months of treatment.
Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European Society of Cardiology.
Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.
The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD).
› Verified 8 days ago
| Entity Name | Gundersen Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20040130000561 |
News Archive
New research led by the University of Bristol, has shown the drug losartan, normally used to treat high blood pressure (hypertension), is not effective in slowing down the progression of Alzheimer's disease (AD) in people with mild-to-moderate disease after 12 months of treatment.
Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European Society of Cardiology.
Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.
The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD).
› Verified 8 days ago
| Entity Name | Gundersen Regional Clinics, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699461558 PECOS PAC ID: 8820450919 Enrollment ID: O20230822002401 |
News Archive
New research led by the University of Bristol, has shown the drug losartan, normally used to treat high blood pressure (hypertension), is not effective in slowing down the progression of Alzheimer's disease (AD) in people with mild-to-moderate disease after 12 months of treatment.
Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European Society of Cardiology.
Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.
The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason A Maret, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Jason A Maret, MD 1830 State Highway 9, Decorah, IA 52101-7301 Ph: (563) 382-3140 |
News Archive
New research led by the University of Bristol, has shown the drug losartan, normally used to treat high blood pressure (hypertension), is not effective in slowing down the progression of Alzheimer's disease (AD) in people with mild-to-moderate disease after 12 months of treatment.
Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European Society of Cardiology.
Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.
The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD).
› Verified 8 days ago
Dr. Kevin Vincent Quinn, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1830 State Highway 9, Decorah, IA 52101 Phone: 563-382-3140 Fax: 563-382-6140 | |
Lalit Gupta, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1830 State Highway 9, Decorah, IA 52101 Phone: 563-382-3140 |